Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more safety data — not another clinical trial — will lead to approval next year.
Continue reading Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year
Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year originally appeared on DailyFinance on Fri, 29 Oct 2010 11:10:00.
Filed Under: Company News, Health Care, Stocks in the News